Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BioBypass · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| BioBypass® | GENETIC | - |
Inclusion Criteria: * Age greater than or equal to 18 years and less than or equal to 80 years; * Written informed consent obtained prior to any study dictated procedure; * Moderate to severe angina (CCS Angina Class II-IV) despite optimal medical therapy; * Treated with optimal unchanged antiangin...
BioBypass is an investigational gene therapy being studied for moderate to severe angina pectoris. It is intended for patients whose chronic angina symptoms are not relieved by medication and who have an area of the heart that cannot be treated by standard therapies.
BioBypass is being developed by Precigen, Inc., which trades under the ticker symbol PGEN. The company is the sponsor of the clinical program evaluating this gene therapy for moderate to severe angina pectoris.
BioBypass is in Phase 2 clinical development. It is an investigational gene therapy and has not been approved by the FDA. The Phase 2 trial has been completed, and no active trials are currently listed for this asset.
BioBypass has been evaluated in one completed Phase 2 clinical trial, NCT00215696. The study enrolled 129 patients with moderate to severe angina pectoris in Denmark and Israel. It was a randomized, double-blind trial for patients whose symptoms were not relieved by medication.
Yes, BioBypass and BioBypass® refer to the same investigational gene therapy developed by Precigen, Inc. The registered trademark symbol is simply a stylized version of the name used in some materials.